NCT04372147View on ClinicalTrials.gov

Embolization of the Middle Meningeal Artery for the Prevention of Chronic Subdural Hematoma Recurrence in High Risk Patients (EMPROTECT)

NACompletedINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

October 23, 2023

Study Completion Date

October 23, 2023

Conditions
Chronic Subdural HematomaAt Risk of Post-operative RecurrenceBurr-hole Surgery
Interventions
PROCEDURE

MMA embolization

Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care

Trial Locations (12)

13015

Hôpital Nord (CHU MARSEILLE), Marseille

13385

CHU de Marseille, Marseille

37044

CHU Tours, Tours

59037

CHU Lille (Hôpital Roger Salengro), Lille

75010

Hôpital Lariboisière, Paris

75013

Hôpital Pitié-Salpêtrière, Paris

75014

Hôpital Sainte Anne, Paris

75019

Fondation Rothschild, Paris

87042

CHU de Limoges, Limoges

92110

Hôpital Beaujon, Clichy

92190

Hôpital d'instruction des armées de Percy, Clamart

94010

Hôpital Henri-Mondor, Créteil

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04372147 - Embolization of the Middle Meningeal Artery for the Prevention of Chronic Subdural Hematoma Recurrence in High Risk Patients (EMPROTECT) | Biotech Hunter | Biotech Hunter